^
Association details:
| Biomarker: | ETV6-NTRK3 fusion + CRTC3-NTRK3 fusion |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis
Published date:
11/22/2022
Excerpt:
A 64-year-old woman presented with metastatic TNBC five years after being treated for a localized breast cancer….NGS evaluation of cfDNA via an 83-gene assay (Guardant Health, Inc.) identified two NTRK3 fusions: an ETV6-NTRK3 fusion...and CRTC3-NTRK3....The patient took larotrectinib for 7 months with good disease control.
